US protection ending in 2035: Cancer
As of the edition of 20 October 2026, 26 drugs have US protection that ends in 2035 in cancer, 25 of them marketed; 15 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
26 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Brigatinib | Ends 2035 (patent) | Marketed | Takeda | ALK, EGFR | 1 |
| Efanesoctocog alfa | Ends 2035 (computed from the first US licence) | Marketed | Bioverativ Therapeutics | 0 | |
| Efbemalenograstim alfa | Ends 2035 (computed from the first US licence) | Marketed | Evive Biotechnology | CSF3R | 2 |
| Elranatamab | Ends 2035 (computed from the first US licence) | Marketed | Pfizer | CD3E, TNFRSF17 | 1 |
| Epcoritamab | Ends 2035 (computed from the first US licence) | Marketed | Merus | CD3D, CD3E, CD3G | 2 |
| Ferric maltol | Ends 2035 (patent) | Marketed | Shield Tx | 0 | |
| Finerenone | Ends 2035 (patent) | Marketed | Bayer | NR3C2 | 0 |
| Fruquintinib | Ends 2035 (patent) | Marketed | Takeda | FLT1, FLT4, KDR | 2 |
| Glofitamab | Ends 2035 (computed from the first US licence) | Marketed | Roche | CD3E, MS4A1 | 0 |
| Lenvatinib | Ends 2035 (patent) | Marketed | Eisai | FLT1, FLT4, KDR | 3 |
| Mobocertinib | Ends 2035 (patent) | Marketed | Takeda | EGFR | 0 |
| Momelotinib | Ends 2035 (patent) | Marketed | GSK | ACVR1, JAK1, JAK2 | 3 |
| Netupitant | Ends 2035 (patent) | Marketed | Helsinn Healthcare | TACR1 | 0 |
| Omidubicel | Ends 2035 (computed from the first US licence) | Marketed | Gamida Cell | 0 | |
| Pafolacianine | Ends 2035 (patent) | Marketed | On Target | FOLR1 | 1 |
| Perflutren | Ends 2035 (patent) | Marketed | Lantheus Medical Imaging | 0 | |
| Pozelimab | Ends 2035 (computed from the first US licence) | Marketed | Regeneron | C5 | 1 |
| Remdesivir | Ends 2035 (patent) | Marketed | Gilead Sciences | 0 | |
| Respiratory syncytial virus pre-fusion glycoprotein f | Ends 2035 (reference-product exclusivity) | Marketed | GSK | 0 | |
| Retifanlimab | Ends 2035 (computed from the first US licence) | Marketed | Incyte | PDCD1 | 1 |
| Rozanolixizumab | Ends 2035 (computed from the first US licence) | Marketed | UCB | FCGRT | 1 |
| Selinexor | Ends 2035 (patent) | Marketed | Karyopharm Therapeutics | XPO1 | 2 |
| Talquetamab | Ends 2035 (computed from the first US licence) | Marketed | Johnson & Johnson | CD3D, CD3E, CD3G | 1 |
| Toripalimab | Ends 2035 (computed from the first US licence) | Marketed | Coherus Oncology | PDCD1 | 2 |
| Umbralisib | Ends 2035 (patent) | Withdrawn from market | TG Therapeutics | ABL1, PIK3CD | 0 |
| Zilucoplan sodium | Ends 2035 (patent) | Marketed | UCB | C5 | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2035 in cancer
In the product15 of these 26 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.